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The last decade has seen many new developments and improved therapies for men 
with metastatic castrate resistant prostate cancer (mCRPC), but the exact 
sequencing of these therapies for any individual man remains uncertain. This is 
partly due to the heterogeneity of prostate cancer and tumour factors such as 
Gleason Grade, PSA kinetics, and the sites of recurrence (visceral, bone or nodal) 
that will influence the sequence in which these drugs are prescribed. Currently there 
is a lack of sufficiently robust biomarkers that predict response or toxicity/tolerability 
of any individual treatment. Patient co-morbidities, potential toxicities of drugs, and 
importantly patient choice depending on their individual circumstances, will also have 
an impact [1].  
The management of mCRPC requires a multidisciplinary team (MDT) approach, with 
the patient receiving information from different specialties. It is therefore important 
that MDT members are aware of each other’s roles and can provide patients with 
accurate and consistent information to guide treatment decisions. The American 
Society of Clinical Oncology (ASCO) guidelines for survivors of prostate cancer 
recommend that an individual’s information needs at all stages of disease are 
assessed and patients provided with or referred to the appropriate sources for 
information and support [2]. However, a series of studies from Canada with men with 
advanced prostate cancer (the majority of whom were castrate resistant), their 
partners, and health professionals identified three areas that needed attention [3-5]. 
These were (a) treatments and associated side effects, (b) progression of the 
disease and (c) available supportive care services.  
As part of an ongoing prospective study examining the EXperiences, TREatments 
and Quality Of Life (EXTREQOL) in men diagnosed with mCRPC, we conducted an 
initial survey between September 2016 and February 2017, exploring the views of 
109 UK Health Care Professionals (HCPs) about the treatment and clinical 
management of mCRPC at their hospitals. 60% of respondents were clinicians 
affiliated to the British Uro-oncology Group (BUG) and 11% nurses from the British 
Association of Urology Nurses (BAUN). Topic areas covered different areas of 
clinical practice including information provision, decision making, treatments, pain 
relief and follow up. The findings highlighted the challenges to providing holistic care 
for this group of men within busy NHS clinics and gaps and inconsistencies in the 
provision of information and use of terminology. 
We know that men with mCRPC report a significantly poorer Quality of Life (QoL) 
and increased pain compared with other groups of prostate cancer patients [6], so 
consultations are likely to take more time, involve pain management and /or 
supportive care referrals. It was apparent that many of the new and follow up clinics 
were understaffed and extremely busy. A common finding was the presence of one 
clinical oncologist (53%) and a research (48%) or oncology nurse (40%).  The 
absence in clinic of palliative care physicians (93%), medical oncologists (67%), 
urologists (65%) and specialist urology nurses (73%) was notable especially as 43% 
nominated pain as the most troubling symptom for patients at presentation. A 
combination of too few staff and resources is detrimental to the well-being of both 
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patients and HCPs in whom it can lead to increased stress and burnout [7, 8]. Part of 
the problem was that many respondents had to manage these patients in general 
urological oncology clinics, alongside others with a variety of different stages of 
prostate cancer and other urological tumours. Having dedicated clinics would enable 
clinicians with a specific interest in this stage of the disease to focus appropriately on 
the perhaps more complex needs of this group of patients and allow added input 
from the palliative care team. There was an appeal from clinicians for more specialist 
nurse support, which needs to double to match that provided for breast cancer 
patients [9].  
The majority of clinicians were able to offer enzalutamide, abiraterone and docetaxel 
as treatment options but others were not routinely available, including radium-233 
(13%), cabazitaxel (14%), mitoxantrone (35%) and denosumab (71%).  We 
acknowledge that single time-point survey data are sensitive to policy changes, 
however, despite evidence that some of these agents may be effective before or 
after chemotherapy, there were restrictions placed on the sequencing of treatments 
in certain geographical locations. As the primary therapeutic aims in mCRPC 
treatments are not only to increase overall survival, and delay progression but also to 
palliate symptoms and improve quality of life, it was disappointing to see how 
infrequently Patient Reported Outcome (PRO) data were collected outside of a trial 
setting (4%). Though advocated, routine PRO use has yet to become the norm [10], 
yet there is growing evidence to show it benefits patients, including increasing 
survival in patients with metastatic cancer [11]. 
Providing the patient agreed, most HCPs always allowed family and friends to be 
present at treatment consultations (85%). 59% said they gave patients as long as 
they needed in order to make a treatment decision, but this was influenced to some 
extent by whether or not patients lived alone. Key questions concerning prognosis 
and how treatments work are best answered by the treating clinician [12]. Important 
as this is, differences emerged between what clinicians and nurse specialists 
believed was covered during the mCRPC diagnostic consultation. Our results 
showed that few always discussed prognosis (26%), side effect amelioration (50%), 
patients’ current goals (38%), and supportive care (24%). Additionally, only 37% 
reported always checking explicitly that patients understood the purpose of their 
treatment. Discussions around these issues can be distressing for both patients and 
family members making some of them avoidant of the subject despite paradoxically 
needing this information to help with treatment decision making.  
Few clinicians (53%) felt confident in being able to ameliorate the side effect of 
fatigue compared to a majority of nurses (71%). Yet fatigue is a key symptom in this 
group of patients, especially those who have received long term androgen 
deprivation therapy, which can lead to reduced bone mineral density, muscle 
mass/strength and physical functioning [13, 14]. Exercise regimes can improve QoL, 
fatigue, fitness and function for men with prostate cancer, but for those who have 
mCRPC with bone metastases the outcome may be different. We await with interest 
the results from a US study of men with mCRPC randomised to 12 months of 
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psychosocial support +/- high intensity aerobic and resistance training, followed by 
self-managed exercise and behavioural support for an additional 12 months [15]. 
HCPs supplemented their own information giving with that contained in National 
Cancer Charity pamphlets or Prostate Cancer Charity leaflets that have links to their 
related websites. Our results showed the majority (85%) said they gave patients 
website information, most often Macmillan (54%) and Prostate Cancer UK (51%). 
Many websites use the term mCRPC though HCPs rarely said they did so with their 
patients (19%); most (56%) preferring the phrase advanced prostate cancer (APC). 
The term ‘castration resistant’, whilst a correct description, has punitive associations 
not welcomed by most patients; Pezaro and colleagues [16] suggest it is time to 
acknowledge that the label may be alienating, recommending the prostate cancer 
community describe it as metastatic or APC.  
This survey revealed the status quo is to manage men with mCRPC in general 
urological oncology clinics which has some clear implications. Staffing levels/mix 
were not conducive to enabling healthcare professionals to be able to focus on the 
often more complex needs of this population and it was evident important topics, 
such as prognosis and amelioration of side-effects, were not routinely discussed in 
the diagnostic consultation. These circumstances make achieving optimal quality of 
life for patients much more challenging. Solutions may lie in dedicated clinics, better 
access to specialist nurses, even a mCRPC nurse role and earlier links to the 
palliative team to draw on their services for the best possible symptom control.  
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